Erich Hinel
Optometrist · Blue Ash, OHNPI 1447563077
Payments from drug & device makers
Across 175 payments — averaging $49.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Tarsus Pharmaceuticals, Inc.$1K
- Eyevance Pharmaceuticals LLC$1K
- Aerie Pharmaceuticals, Inc.$484
- Bausch & Lomb Americas Inc.$459
- AbbVie$434
- plus $3K from 18 others
What the payments were for
- Consulting fees$1,90022%
- Travel & lodging$1,16414%
- Food & beverage$5,55564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 16 | $1,611 |
| Tarsus Pharmaceuticals, Inc. | 17 | $1,445 |
| Eyevance Pharmaceuticals LLC | 3 | $1,205 |
| Aerie Pharmaceuticals, Inc. | 16 | $484 |
| Bausch & Lomb Americas Inc. | 13 | $459 |
| AbbVie(2 entities) | 17 | $434 |
| Sun Pharmaceutical Industries Inc. | 17 | $401 |
| Dompe US, Inc. | 7 | $357 |
| Harrow Eye, LLC | 8 | $336 |
| Astellas Pharma US Inc | 6 | $306 |
| Alcon | 10 | $292 |
| Mallinckrodt Hospital Products Inc. | 10 | $285 |
| Oyster Point Pharma, Inc. | 7 | $241 |
| Regeneron Healthcare Solutions, Inc. | 7 | $211 |
| Apellis Pharmaceuticals, Inc. | 2 | $152 |
| ANI Pharmaceuticals, Inc. | 3 | $94 |
| Novartis | 4 | $85 |
| Alimera Sciences, Inc. | 4 | $81 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $34 |
| Kala Pharmaceuticals, Inc. | 2 | $33 |
| Lombart Brothers, Inc. | 1 | $30 |
| Eyepoint US, Inc. | 1 | $16 |
| Immunogen, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,620 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 70 | $75,685 |
| RhopressaNetarsudil Mesylate | 111 | $53,103 |
| XiidraLifitegrast | 40 | $48,550 |
| Alphagan PBrimonidine Tartrate | 109 | $40,755 |
| Difluprednate | 121 | $38,002 |
| MieboPerfluorohexyloctane/Pf | 23 | $35,215 |
| XdemvyLotilaner | 14 | $26,046 |
| CombiganBrimonidine Tartrate/Timolol | 63 | $25,875 |
| LumiganBimatoprost | 61 | $24,161 |
| Fluorometholone | 282 | $20,230 |
| Prednisolone Acetate | 447 | $19,197 |
| Brimonidine Tartrate | 565 | $18,133 |
| Cyclosporine | 44 | $14,089 |
| MoxifloxacinMoxifloxacin Hcl | 224 | $14,022 |
| CequaCyclosporine | 18 | $13,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Combigan, Lumigan | $434 | $166,477303 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Zirgan, Vyzulta | $459 | $105,05799 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $484 | $65,609135 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,445 | $26,04614 claims |
| AlconSimbrinza, Azopt | $292 | $17,32766 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $401 | $13,93218 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Loteprednol Etabonate | $34 | $10,76653 claims |
| NovartisDurezol | $85 | $5,90913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.
Other optometrist in Blue Ash
- Daniel HageeBlue Ash$58K
- Katherine BickleGranville$3M
- Jennifer FogtColumbus$1.9M
- Jason MillerPowell$1.4M
- Mile BrujicBowling Green$1.3M
- William LayWesterville$891K
- Gregory DenaeyerColumbus$846K
- Thomas ChesterCleveland$786K
- Loretta Szczotka-FlynnCleveland$388K
- Cory LappinMontgomery$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.